• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Harrow Inc.

    2/13/24 5:06:13 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    SC 13G 1 tv01078-harrowinc.htm SCHEDULE 13G harrowinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Harrow Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  415858109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  415858109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    54,775

    7.  SOLE DISPOSITIVE POWER

    1,728,920

    8.  SHARED DISPOSITIVE POWER

    79,632

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,808,552

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.15%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Harrow Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    102 Woodmont Boulevard, Suite 610
    Nashville, TN 37205

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    415858109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $HROW alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

      Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYOOVIZ has been commercialized

      7/17/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

      Harrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen's commercialization rights back to Samsung Bioepis by the end of 2025 BYOOVIZ, approved by the FDA in September 2021 as the first ophthalmology biosimilar in the US, has been commercially available since June 2022 OPUVIZ was approved by the FDA in May 2024 Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (NASDAQ:HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUC

      7/17/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

      6/18/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Harrow with a new price target

      Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

      7/11/25 8:12:59 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Harrow with a new price target

      BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

      6/12/25 7:54:43 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Harrow

      William Blair initiated coverage of Harrow with a rating of Outperform

      6/10/25 8:09:06 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/25/24 5:19:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/24/24 4:40:20 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/19/24 6:24:32 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    SEC Filings

    See more
    • Harrow Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - HARROW, INC. (0001360214) (Filer)

      7/17/25 7:16:10 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Harrow Inc.

      S-8 - HARROW, INC. (0001360214) (Filer)

      6/20/25 7:22:12 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - HARROW, INC. (0001360214) (Filer)

      6/20/25 6:01:59 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Baum Mark L covered exercise/tax liability with 313,338 shares and exercised 600,000 shares at a strike of $7.87, increasing direct ownership by 11% to 2,886,124 units (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      7/23/25 9:10:48 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Boll Andrew R.

      4 - HARROW, INC. (0001360214) (Issuer)

      7/1/25 4:45:26 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Baum Mark L

      4 - HARROW, INC. (0001360214) (Issuer)

      7/1/25 4:45:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    See more
    • Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

      6/18/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

      1/7/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

      5/13/24 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      12/5/24 7:08:52 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      10/8/24 6:41:41 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      2/13/24 5:25:53 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Financials

    Live finance-specific insights

    See more
    • Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin

      6/9/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care